President and Chief Executive Officer
Dr. Pons previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of three antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron. Dr. Pons earned his Ph.D. in molecular and cell biology at the Institute on Fundamental Biology, Barcelona, Spain and an M.S. in biotechnology and B.S. in biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.
Chief Financial Officer
Mr. Borgeson’s prior experience includes over 20 years at Pfizer where he was a member of Pfizer’s Global Financial Leadership Team and held several financial positions of increasing responsibility. His most recent role at Pfizer was Vice President, Finance for Pfizer’s biotherapeutic research division where he had broad strategic, financial and operational responsibility over building Pfizer’s biotechnology franchise. Since leaving Pfizer in 2010, Mr. Borgeson has led finance for a variety of private companies, including Labrys Biologics, Solstice Biologics and Heart Metabolics. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Mr. Borgeson started his career at Ernst & Young and is a certified public accountant. He has an MBA from the Rochester Institute of Technology (RIT) and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Chief Medical Officer
Dr. Randolph previously served as Franchise Clinical Lead for the IBRANCE® clinical program at Pfizer, Inc., leading the early and late clinical development of this asset with initial registrations in the U.S. and rest of world. Before joining Pfizer, Dr. Randolph served as ZOLINZA® Clinical Lead at Merck, Inc., responsible for design and implementation of its hematology clinical life cycle plan as well as Molecular Profiling Lead, creating clinical trial translational plans across several oncology early development programs. Dr. Randolph received her M.D. and Ph.D. in cellular and molecular biology from University of Michigan and completed her oncology fellowship training at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center where she studied hematopoietic cell transplant engineering methods to improve the graft-versus-leukemia effect for transplant patients. Dr. Randolph received her A.B. in biochemistry from Harvard University.
Chief Scientific Officer
Dr. Wan previously served as Senior Director, Biotechnology Clinical Development at Rinat (Pfizer), where she was responsible for the early development and translational medicine strategy across various therapeutic areas. Prior to that, Dr. Wan held positions as Director, Translational and Molecular Medicine at Pfizer and Director, Clinical Translational Medicine at Wyeth. Before joining Wyeth, Dr. Wan was Project Lead and Senior Scientist at Renovis. Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.
Vice President, Operations
Dr. Chang was on the founding management team as VP Project Management at Labrys Biologics, which was acquired by Teva Pharmaceuticals. Prior to Labrys, Dr. Chang held positions as VP Project Management and Team Leader for RANEXA® at CV Therapeutics up until its acquisition by Gilead. Before that time, Dr. Chang managed the development and registration of VIRACEPT® at Agouron Pharmaceuticals, which was subsequently acquired by Pfizer. Dr. Chang earned his Ph.D. in microbiology and immunology from the University of California, Los Angeles and B.S. with honors from the University of California, Los Angeles. He conducted his post-doctoral training at the University of California, San Francisco as a Leukemia Society of America Research Fellow.
Vice President, Chemistry, Manufacturing, and Controls
Mr. Stern has worked in the biopharmaceutical industry for over 32 years in a variety of leadership roles encompassing operations, contracts, drug development, and plant management at Teva Pharmaceuticals, Labrys Biologics, and Genentech. Mr. Stern has worked extensively in both drug substance and drug product for commercial and development products, including high concentration products and devices. His work has been instrumental in advancing new therapies from research into the clinic and large-scale commercial manufacturing. Mr. Stern earned his B.S. degree in fermentation science from University of California, Davis and MBA from San Francisco State University.
Acting General Counsel
Dr. Warner previously held the positions of Assistant General Counsel and Legal Site Head for Pfizer’s Rinat subsidiary, and was lead counsel to Pfizer’s Medicinal Chemistry and Pharmaceutical Sciences divisions. In addition, Dr. Warner is a registered patent attorney and formerly was the head of Pfizer’s St. Louis patent department. He has been the lead attorney for numerous successful outlicensing projects including Pfizer’s spin-off of RaQualia Pharma (Japan), and he has more than 35 years of experience as an attorney and a researcher in the life sciences. He earned his Ph.D. in organic chemistry from Indiana University, J.D. from St. Louis University, and B.S. with honors in chemistry at Centenary College of Louisiana.